Founder: Shiv Rao (CEO)
Launched: 2018
Headquarters: San Francisco
Funding: $830 million
Valuation: $5.3 billion
Key Technologies: Artificial intelligence, deep neural networks/deep learning, generative AI, machine learning
Industry: Health care
Previous appearances on Disruptor 50 list: 1 (No. 47 in 2025)
Abridge is part of a wave of companies changing one of the most broken processes in healthcare by recording conversations between providers and patients (with consent), and automatically transcribing them. Healthcare documentation is notoriously burdensome, adding as much as 30% to total health spending in the United States and costing clinicians as much as a third of their time.
Over the past year, Abridge raised $550 million in Series D and E venture rounds, using the infusion of cash to go deeper into medical decision-making. It introduced products that inject clinical decision support and peer-reviewed research into clinical notes. And it expanded into an additional 150 health systems for a total of 250, including giants such as Johns Hopkins and Kaiser Permanente.
Shiv Rao, a practicing cardiologist, founded Abridge to solve the clinician burnout problem caused by hours of record-making. Competitors include Microsoft's DAX Copilot, as well as a broader set of AI startups focused on the medical profession, including fellow Disruptor OpenEvidence.
Investments in AI accounted for 46% of total healthcare investment in 2025, according to Silicon Valley Bank's latest report on investments and exits, but overall investment in the sector is slowing — suggesting that the market for AI-driven disruption of health care remains hot, but winners are emerging.
Abridge sees huge opportunity in a U.S. healthcare system that spends an estimated $1.5 trillion on administrative costs annually, with clinical documentation a significant chunk of that. Abridge estimates that all of the administrative work requires physicians to find "30 hours in a day to keep up."
The race for scale and efficiency is driving disruptors into new territory. Rao has described some of the new directions to more tightly integrate healthcare delivery with payor systems as a way to drive efficiency. For instance, Abridge's system may hear a spoken conversation between a doctor and patient, and map the spoken conversation to a new diagnostic code, helping a health system get paid faster, Rao told the Pioneers of AI podcast. And AI-driven prescription refills may be on the horizon, Rao has said, though states, such as Utah, are starting to push back against these efforts.
Abridge's blue-chip investors include Andreessen Horowitz, IVP and Elad Gil. It also has backing from the venture arms of Kaiser Permanente, CVS and Nvidia.
Sign up for our weekly, original newsletter that goes beyond the annual Disruptor 50 list, offering a closer look at the most promising venture-backed companies.
